Availability of clinical trials investigating prostate cancer (PC) in the United States (US).
Benjamin Mercier(City of Hope), Sumanta Kumar Pal(City Of Hope National Medical Center), Ruchi Agarwal(University of Pennsylvania), Charles B. Nguyen(City of Hope), Daniela V. Castro(City of Hope), Akasha Dukkipati(City of Hope), Koral Shah(City of Hope), Vitor Góes(City of Hope), Ruth Simon(City of Hope), Jaya Goud(City of Hope), Samuel Dickter(City of Hope), Nazli Dizman(The University of Texas MD Anderson Cancer Center), Salvador Jaime-Casas(City of Hope), Regina Barragan-Carrillo(City of Hope), George Zhang(City of Hope), Alex Chehrazi-Raffle(City of Hope), Joshua Lee(City of Hope), Miguel Zugman(City of Hope), Lily Lau(City of Hope), Xiaochen Li(City of Hope)
Cited by 0
Related Papers
BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells
|Brain|2018|133
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1